Aim of the work: To investigate the frequency of FoxP3+CD4+CD25+high cells (Tregs) in rheumatoid arthritis (RA) patients and their association with clinical and radiological parameters. Also to study the possible relationship between Tregs and TGF-b as an indicator of Treg function, with IL17 as an indicator of Th17 function and with the ratio between them to throw light on the imbalance between these two cytokines in RA.Patients and methods: Forty RA patients and 20 age and sex matched healthy controls were enrolled in the study. Patients underwent clinical, laboratory and radiographic assessment. The frequency of Tregs was determined by flowcytometry. Serum IL-17 and TGF-b cytokines were analyzed using ELISA.Results: The frequency of Tregs was significantly decreased among RA patients and with a parallel significant decrease in the mean fluorescence intensity (MFI) of FoxP3. Both IL-17 and TGFb were significantly increased. Tregs, IL-17 and TGF-b did not correlate with any of the clinical findings, laboratory and radiographic scores. TGFb:IL-17 ratio dropped from 15.8 ± 9.6 among controls to 5.33 ± 5 among patients with mild-to-moderate activity and 2.45 ± 1.8 among patients with severe activity.Conclusion: RA patients show a decreased frequency of Tregs that is not associated with clinical parameters or radiological damage. The five-fold increase in IL-17 and two-fold increase in TGF-b prove a disturbance in the balance of the cytokine milieu in favor of inflammation and draw attention to the importance of considering the interplay of the Treg/TH17 cytokine axis in the pathogenesis of RA; hence aiming at restoring that balance during treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.